Differential structural remodelling of heparan sulfate by chemokines: The role of chemokine oligomerization

Open Biology

Volumn 7, Issue 1, 2017, Pages

  Dyer, Douglas P ^a,b   Migliorini, Elisa ^c,d   Salanga, Catherina L ^a   Thakar, Dhruv ^d   Handel, Tracy M ^a   Richter, Ralf P ^c,d,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c CIC BIOMAGUNE   (Spain)

^d UNIVERSITÉ JOSEPH FOURIER   (France)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Chemokine; Extracellular matrix; Glycocalyx; Glycosaminoglycan; Heparan sulfate; Quartz crystal microbalance with dissipation monitoring

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; HEPARAN SULFATE; PROTEIN BINDING;

ANIMAL; BINDING SITE; CELL ADHESION; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

ANIMALS; BINDING SITES; CELL ADHESION; CHEMOKINES; HEPARITIN SULFATE; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 85012912282     PISSN: None     EISSN: 20462441     Source Type: Journal    
DOI: 10.1098/rsob.160286     Document Type: Article

References (78)

1. Turnbull J, Powell A, Guimond S. 2001 Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 11, 75-82. (doi:10.1016/S0962-8924(00)01897-3)
2. Xu D, Esko JD. 2014 Demystifying heparan sulfateprotein interactions. Annu. Rev. Biochem. 83, 129-157. (doi:10.1146/annurev-biochem-060713-035314)
3. Götte M. 2003 Syndecans in inflammation. FASEB J. 17, 575-591. (doi:10.1096/fj.02-0739rev)
4. Ori A, Wilkinson MC, Fernig DG. 2011 A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J. Biol. Chem. 286, 19 892-19 904. (doi:10.1074/jbc.M111.228114)
5. Constantinescu AA, Vink H, Spaan JAE. 2003 Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler. Thromb. Vasc. Biol. 23, 1541-1547. (doi:10.1161/01.ATV.0000085630.24353.3D)
6. van den Berg BM, Vink H, Spaan JAE. 2003 The endothelial glycocalyx protects against myocardial edema. Circ. Res. 92, 592-594. (doi:10.1161/01. RES.0000065917.53950.75)
7. van den Berg BM, Spaan JAE, Vink H. 2009 Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Pflugers Arch. 457, 1199-1206. (doi:10.1007/s00424-008-0590-6)
8. Reitsma S, Oude Egbrink MGA, Heijnen VVT, Megens RTA, Engels W, Vink H., Slaaf DW, van Zandvoort MAMJ. 2011 Endothelial glycocalyx thickness and platelet-vessel wall interactions during atherogenesis. Thromb. Haemost. 106, 939-946. (doi:10.1160/TH11-02-0133)
9. Tarbell JM, Ebong EE. 2008 The endothelial glycocalyx: a mechano-sensor and -transducer. Sci. Signal. 1, pt8-pt8. (doi:10.1126/scisignal.140pt8)
10. Schmidt EP et al. 2012 The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat. Med. 18, 1217-1223. (doi:10.1038/nm.2843)
11. Tarbell JM, Cancel LM. 2016 The glycocalyx and its significance in human medicine. J. Intern. Med. 280, 97-113. (doi:10.1111/joim.12465)
12. Wiesinger A, Peters W, Chappell D, Kentrup D, Reuter S, Pavenstädt H, Oberleithner H, Kümpers P. 2013 Nanomechanics of the endothelial glycocalyx in experimental sepsis. PLoS ONE 8, e80905. (doi:10.1371/journal.pone.0080905)
13. Mulivor AW, Lipowsky HH. 2004 Inflammation- and ischemia-induced shedding of venular glycocalyx. Am. J. Physiol. Heart Circ. Physiol. 286, H1672-H1680. (doi:10.1152/ajpheart.00832.2003)
14. Marki A, Esko JD, Pries AR, Ley K. 2015 Role of the endothelial surface layer in neutrophil recruitment. J. Leukoc. Biol. 98, 503-515. (doi:10.1189/jlb. 3MR0115-011R)
15. Schmidt EP, Lee WL, Zemans RL, Yamashita C, Downey GP. 2011 On, around, and through: neutrophil-endothelial interactions in innate immunity. Physiology 26, 334-347. (doi:10.1152/physiol.00011.2011)
16. Luster AD. 1998 Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338, 436-445. (doi:10.1056/NEJM199802123380706)
17. Sallusto F, Baggiolini M. 2008 Chemokines and leukocyte traffic. Nat. Immunol. 9, 949-952. (doi:10.1038/ni.f.214)
18. Bachelerie F et al. 2014 International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66, 1-79. (doi:10.1124/pr.113.007724)
19. Salanga CL, Handel TM. 2011 Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317, 590-601. (doi:10.1016/j.yexcr.2011.01.004)
20. Proudfoot AEI, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TNC, Kosco-Vilbois MH. 2003 Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl Acad. Sci. USA 100, 1885-1890. (doi:10.1073/pnas.0334864100)
21. Tanino Y et al. 2010 Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs. J. Immunol. 184, 2677-2685. (doi:10.4049/jimmunol.0903274)
22. O'Boyle G, Mellor P, Kirby JA, Ali S. 2009 Antiinflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J. 23, 3906-3916. (doi:10.1096/fj.09-134643)
23. Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA. 2005 A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokinemediated inflammation. J. Immunol. 175, 1257-1266. (doi:10.4049/jimmunol.175.2.1257)
24. Dyer DP, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AEI, Day AJ, Milner CM. 2014 TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J. Immunol. 192, 2177-2185. (doi:10.4049/jimmunol.1300194)
25. Dyer DP, Salanga CL, Johns SC, Valdambrini E, Fuster MM, Milner CM, Day AJ, Handel TM. 2016 The anti-inflammatory protein TSG-6 regulates chemokine function by inhibiting chemokine/glycosaminoglycan interactions. J. Biol. Chem. 291, 12 627-12 640. (doi:10.1074/jbc.M116.720953)
26. Gangavarapu P, Rajagopalan L, Kolli D, Guerrero-Plata A, Garofalo RP, Rajarathnam K. 2012 The monomer-dimer equilibrium and glycosaminoglycan interactions of chemokine CXCL8 regulate tissuespecific neutrophil recruitment. J. Leukoc. Biol. 91, 259-265. (doi:10.1189/jlb.0511239)
27. Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF, Luther SA, Bollenbach T, Sixt M. 2013 Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339, 328-332. (doi:10.1126/science.1228456)
28. Sarris M, Masson J-B, Maurin D, Van der Aa LM, Boudinot P, Lortat-Jacob H, Herbomel P. 2012 Inflammatory chemokines direct and restrict leukocyte migration within live tissues as glycanbound gradients. Curr. Biol. 22, 2375-2382. (doi:10.1016/j.cub.2012.11.018)
29. Migliorini E et al. 2015 Cytokines and growth factors cross-link heparan sulfate. Open Biol. 5, 150 046. (doi:10.1098/rsob.150046)
30. Baranova NS, Nileback E, Haller FM, Briggs DC, Svedhem S, Day AJ, Richter RP. 2011 The inflammation-associated protein TSG-6 cross-links hyaluronan via hyaluronan-induced TSG-6 oligomers. J. Biol. Chem. 286, 25 675-25 686. (doi:10.1074/jbc.M111.247395)
31. Day AJ, la Motte de CA. 2005 Hyaluronan crosslinking: a protective mechanism in inflammation? Trends Immunol. 26, 637-643. (doi:10.1016/j.it. 2005.09.009)
32. Salanga CL, Dyer DP, Kiselar JG, Gupta S, Chance MR, Handel TM. 2014 Multiple glycosaminoglycanbinding epitopes of monocyte chemoattractant protein-3/CCL7 enable it to function as a nonoligomerizing chemokine. J. Biol. Chem. 289, 14 896-14 912. (doi:10.1074/jbc.M114.547737)
33. Dyer DP, Salanga CL, Volkman BF, Kawamura T, Handel TM. 2016 The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization. Glycobiology 26, 312-326.
34. Kim KS, Rajarathnam K, Clark-Lewis I, Sykes BD. 1996 Structural characterization of a monomeric chemokine: monocyte chemoattractant protein-3. FEBS Lett. 395, 277-282. (doi:10.1016/0014-5793(96)01024-1)
35. Booth V, Clark-Lewis I, Sykes BD. 2004 NMR structure of CXCR3 binding chemokine CXCL11 (ITAC). Protein Sci. 13, 2022-2028. (doi:10.1110/ps. 04791404)
36. Severin IC et al. 2010 Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. J. Biol. Chem. 285, 17 713-17 724. (doi:10.1074/jbc.M109.082552)
37. Handel TM, Domaille PJ. 1996 Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 35, 6569-6584. (doi:10.1021/bi9602270)
38. Lau EK, Paavola CD, Johnson Z, Gaudry J-P, Geretti E, Borlat F, Kungl AJ, Proudfoot AE, Handel TM. 2004 Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J. Biol. Chem. 279, 22 294-22 305. (doi:10.1074/jbc.M311224200)
39. Clore GMG, Appella EE, Yamada MM, Matsushima KK, Gronenborn AMA. 1990 Three-dimensional structure of interleukin 8 in solution. Biochemistry 29, 1689-1696. (doi:10.1021/bi00459a004)
40. Joseph PRB, Mosier PD, Desai UR, Rajarathnam K. 2015 Solution NMR characterization of chemokine CXCL8/IL-8 monomer and dimer binding to glycosaminoglycans: structural plasticity mediates differential binding interactions. Biochem. J. 472, 121-133. (doi:10.1042/BJ20150059)
41. Zhang XX, Chen LL, Bancroft DPD, Lai CKC, Maione TET. 1994 Crystal structure of recombinant human platelet factor 4. Biochemistry 33, 8361-8366. (doi:10.1021/bi00193a025)
42. Loscalzo J, Melnick B, Handin RI. 1985 The interaction of platelet factor four and glycosaminoglycans. Arch. Biochem. Biophys. 240, 446-455. (doi:10.1016/0003-9861(85)90049-9)
43. Liang WG, Triandafillou CG, Huang T-Y, Zulueta MML, Banerjee S, Dinner AR, Hung S-C, Tang W-J. 2016 Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3. Proc. Natl Acad. Sci. USA 113, 5000-5005. (doi:10.1073/pnas.1523981113)
44. Proudfoot AE et al. 2001 The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J. Biol. Chem. 276, 10 620-10 626. (doi:10.1074/jbc.M010867200)
45. Rajarathnam K, Sykes BD, Kay CM, Dewald B, Geiser T, Baggiolini M, Clark-Lewis I. 1994 Neutrophil activation by monomeric interleukin-8. Science 264, 90-92. (doi:10.1126/science.8140420)
46. Paavola CD et al. 1998 Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J. Biol. Chem. 273, 33 157-33 165. (doi:10.1074/jbc.273.50. 33157)
47. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, Heveker N, Volkman BF, Dwinell MB. 2011 Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl Acad. Sci. USA 108, 17 655-17 660. (doi:10.1073/pnas.1101133108)
48. Baranova NS, Foulcer SJ, Briggs DC, Tilakaratna V, Enghild JJ, Milner CM, Day AJ, Richter RP. 2013 Inter-α-inhibitor impairs TSG-6-induced hyaluronan cross-linking. J. Biol. Chem. 288, 29 642-29 653. (doi:10.1074/jbc.M113.477422)
49. Migliorini E, Thakar D, Sadir R, Pleiner T, Baleux F, Lortat-Jacob H, Coche-Guerente L, Richter RP. 2014 Well-defined biomimetic surfaces to characterize glycosaminoglycan-mediated interactions on the molecular, supramolecular and cellular levels. Biomaterials 35, 8903-8915. (doi:10.1016/j. biomaterials.2014.07.017)
50. Reviakine I, Johannsmann D, Richter RP. 2011 Hearing what you cannot see and visualizing what you hear: interpreting quartz crystal microbalance data from solvated interfaces. Anal. Chem. 83, 8838-8848. (doi:10.1021/ac201778h)
51. Thakar D, Migliorini E, Coche-Guerente L, Sadir R, Lortat-Jacob H, Boturyn D, Renaudet O, Labbe P, Richter RP. 2014 A quartz crystal microbalance method to study the terminal functionalization of glycosaminoglycans. Chem. Commun. 50, 15 148-15 151. (doi:10.1039/C4CC06905F)
52. Clore GM, Gronenborn AM. 1995 Three-dimensional structures of alpha and beta chemokines. FASEB J. 9, 57-62.
53. Czaplewski LG et al. 1999 Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J. Biol. Chem. 274, 16 077-16 084. (doi:10.1074/jbc.274.23.16077)
54. Rauova L et al. 2005 Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105, 131-138. (doi:10.1182/blood-2004-04-1544)
55. Couchman JR. 2003 Syndecans: proteoglycan regulators of cell-surface microdomains? Nat. Rev. Mol. Cell Biol. 4, 926-937. (doi:10.1038/nrm1257)
56. Henry CB, Duling BR. 2000 TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am. J. Physiol. Heart Circ. Physiol. 279, H2815-H2823.
57. Lubkowski J, Bujacz G, Boqué L, Domaille PJ, Handel TM, Wlodawer A. 1997 The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat. Struct. Biol. 4, 64-69. (doi:10.1038/nsb0197-64)
58. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ., Wells TNC. 1999 Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38, 12 959-12 968. (doi:10.1021/bi990711d)
59. Mantovani A. 1999 The chemokine system: redundancy for robust outputs. Immunol. Today 20, 254-257. (doi:10.1016/S0167-5699(99)01469-3)
60. Zhao Y, Chien S, Weinbaum S. 2001 Dynamic contact forces on leukocyte microvilli and their penetration of the endothelial glycocalyx. Biophys. J. 80, 1124-1140. (doi:10.1016/S0006-3495(01)76090-0)
61. Chappell D, Dörfler N, Jacob M, Rehm M, Welsch U, Conzen P, Becker BF. 2010 Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion. Shock 34, 133-139. (doi:10.1097/SHK. 0b013e3181cdc363)
62. Ramnath R et al. 2014 Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor α: a contributor to endothelial cell glycocalyx dysfunction. FASEB J. 28, 4686-4699. (doi:10.1096/fj.14-252221)
63. Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, Conzen P, Becker BF. 2009 TNFalpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res. Cardiol. 104, 78-89. (doi:10.1007/s00395-008-0749-5)
64. Slimani H et al. 2003 Binding of the CC-chemokine RANTES to syndecan-1 and syndecan-4 expressed on HeLa cells. Glycobiology 13, 623-634. (doi:10.1093/glycob/cwg083)
65. Charnaux N, Brule S, Hamon M, Chaigneau T, Saffar L, Prost C, Lievre N, Gattegno L. 2005 Syndecan-4 is a signaling molecule for stromal cell-derived factor-1 (SDF-1)/CXCL12. FEBS J. 272, 1937-1951. (doi:10.1111/j.1742-4658.2005.04624.x)
66. Woods A, Couchman JR. 2001 Syndecan-4 and focal adhesion function. Curr. Opin. Cell Biol. 13, 578-583. (doi:10.1016/S0955-0674(00)00254-4)
67. Lambaerts K, Wilcox-Adelman SA, Zimmermann P. 2009 The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr. Opin. Cell Biol. 21, 662-669. (doi:10.1016/j.ceb.2009.05.002)
68. Gopal S, Bober A, Whiteford JR, Multhaupt HAB, Yoneda A, Couchman JR. 2010 Heparan sulfate chain valency controls syndecan-4 function in cell adhesion. J. Biol. Chem. 285, 14 247-14 258. (doi:10.1074/jbc.M109.056945)
69. Tkachenko E, Elfenbein A, Tirziu D, Simons M. 2006 Syndecan-4 clustering induces cell migration in a PDZ-dependent manner. Circ. Res. 98, 1398-1404. (doi:10.1161/01.RES.0000225283. 71490.5a)
70. Brule S et al. 2006 The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16, 488-501. (doi:10.1093/glycob/cwj098)
71. Charnaux N et al. 2005 RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44. Glycobiology 15, 119-130. (doi:10.1093/glycob/cwh148)
72. Roscic-Mrkic B et al. 2003 RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 102, 1169-1177. (doi:10.1182/blood-2003-02-0488)
73. Maillard L et al. 2014 RANTES/CCL5 mediatedbiological effects depend on the syndecan-4/PKCα signaling pathway. Biol. Open 3, 995-1004. (doi:10.1242/bio.20148227)
74. Allen SJ, Hamel DJ, Handel TM. 2011 A rapid and efficient way to obtain modified chemokines for functional and biophysical studies. Cytokine 55, 168-173. (doi:10.1016/j.cyto.2011.05.002)
75. O'Hayre M, Salanga CL, Dorrestein PC, Handel TM. 2009 Phosphoproteomic analysis of chemokine signaling networks. Methods Enzymol. 460, 331-346. (doi:10.1016/S0076-6879(09)05216-1)
76. Jasnin M, van Eijck L, Koza MM, Peters J, Laguri C, Lortat-Jacob H, Zaccai G. 2010 Dynamics of heparan sulfate explored by neutron scattering. Phys. Chem. Chem. Phys. 12, 3360-3362. (doi:10.1039/b923878f)
77. Eisele NB, Frey S, Piehler J, Görlich D, Richter RP. 2010 Ultrathin nucleoporin phenylalanine-glycine repeat films and their interaction with nuclear transport receptors. EMBO Rep. 11, 366-372. (doi:10.1038/embor.2010.34)
78. Kühnle J. 2007 Lipid assemblies on nanostructured surfaces. Diploma thesis, Faculty of Physics and Astronomy, University of Heidelberg, Heidelberg, Germany.